Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01611766

Recruitment Status : Unknown

Verified June 2021 by Shanghai Gynecologic Oncology Group.
Recruitment status was: Active, not recruiting

First Posted : June 5, 2012

Last Update Posted : June 10, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Fudan University

Zhejiang Cancer Hospital

Shanghai Zhongshan Hospital

Sun Yat-sen University

Information provided by (Responsible Party):

Shanghai Gynecologic Oncology Group

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Actual Primary Completion Date :	December 2019
Estimated Study Completion Date :	December 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8.

To Top